Sign In
Buy SMMT
$15.07
+0.210 (+1.41%)
At Close: Jun 03, 2026
Summit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress Transcript
What's Going On With Summit Therapeutics Stock On Monday?
10:56am, Monday, 01'st Jun 2026
Summit Therapeutics Inc. (NASDAQ:SMMT) stock is down on Monday following the recent announcement regarding the clinical trial results of ivonescimab on Sunday.
Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet
10:56am, Monday, 01'st Jun 2026
The consensus price target hints at a 67.1% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
06:34am, Monday, 01'st Jun 2026
Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients live 15% longer than BeOne Medicines
This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced
01:45pm, Sunday, 31'st May 2026
Biotech companies have always licensed programs, but never so many from one region in particular.
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and spons
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and sponsored by
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
08:00am, Sunday, 31'st May 2026
An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to results being presented at the American Society of
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
09:00am, Saturday, 30'th May 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
08:00am, Saturday, 30'th May 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in first-
Here's Why You Should Add SMMT Stock to Your Portfolio Now
10:31am, Friday, 22'nd May 2026
Summit Therapeutics advances ivonescimab with late-stage NSCLC and CRC studies, with FDA review underway and new partnerships expanding its oncology reach.
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
02:22pm, Monday, 18'th May 2026
/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody
Cancer Stocks That Are Advancing the Future of Oncology Care
01:01pm, Monday, 18'th May 2026
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback
02:15pm, Monday, 04'th May 2026
Summit Therapeutics posts narrower Q1 loss but stock plunges 25% after ivonescimab setback, raising concerns over its late-stage cancer pipeline progress.
Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways
11:07am, Monday, 04'th May 2026
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA deci
